BELGRADE, Mont., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that management will participate in two upcoming investor conferences:
Canaccord Genuity 2024 Musculoskeletal Conference – February 12
A live webcast of the Canaccord presentation will be available on the Investors section of the Company’s website at www.xtantmedical.com. A replay of the webcast will be available following the conclusion of the presentation.
BTIG Medtech, Digital Health, Life Science and Diagnostic Tools Conference – February 13 - 14
About Xtant Medical Holdings, Inc.
Xtant Medical’s mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.
Investor Relations Contact
David Carey
Lazar FINN
Ph: 212-867-1762
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.72 |
| Daily Change: | -0.0065 -0.89 |
| Daily Volume: | 71,349 |
| Market Cap: | US$100.090M |
November 12, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
